anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Eligible women are asked to complete a structured interview, questionnaires, a monthly menstrual diary, a brief physical examination, a blood test, and an abdominal or pelvic ultrasound at baseline and at 3 month intervals following start of chemotherapy through 6 months post end of treatment.

Within subject changes in continuous variables (hormones, urinary isoprostane levels, ovarian volume, AFC) will be compared using paired t-tests (nonparametric tests as appropriate). Non-Gaussian-distributed variables will be logarithmically transformed prior to analysis. In general, changes from baseline to every 3 month assessment will be compared individually as well as changes from baseline to post treatment. In addition, regression models for repeated measures will be used to describe the pattern of change in these outcomes over time. Additional models will be constructed to adjust for potential confounding variables including age, chemotherapy type, dose and duration of treatment, radiation treatment, gonadotropin releasing hormone agonist use, and hormone use. Finally, regression models will be used to evaluate the association between changes in urinary isoprostane levels over the study with changes in endocrine measures.
The intervention is twice daily dosage of Theracurmin 90 mg capsules. This same dose was used in a successful trial of patients with mild cognitive impairment. Theracurmin HP capsules containing 90 mg curcumin each that will be taken as one capsule twice daily for 6 months. Each capsule contains 300 mg Theracurmin enhanced bioavailable water-dispersible turmeric rhizome complex providing 30% curcumin (90 mg). The content of Theracurmin HP has been independently certified by NSF International under NSF/ANSI 173.
AIMS: Cyclophilin A (CyPA) induces leucocyte recruitment and platelet activation upon release into the extracellular space. Extracellular CyPA therefore plays a critical role in immuno-inflammatory responses in tissue injury and thrombosis upon platelet activation. To date, CD147 (EMMPRIN) has been described as the primary receptor mediating extracellular effects of CyPA in platelets and leucocytes. The receptor for advanced glycation end products (RAGE) shares inflammatory and prothrombotic properties and has also been found to have similar ligands as CD147. In this study, we investigated the role of RAGE as a previously unknown interaction partner for CyPA.
METHODS AND RESULTS: Confocal imaging, proximity ligation, co-immunoprecipitation, and atomic force microscopy were performed and demonstrated an interaction of CyPA with RAGE on the cell surface. Static and dynamic cell adhesion and chemotaxis assays towards extracellular CyPA using human leucocytes and leucocytes from RAGE-deficient Ager-/- mice were conducted. Inhibition of RAGE abrogated CyPA-induced effects on leucocyte adhesion and chemotaxis in vitro. Accordingly, Ager-/- mice showed reduced leucocyte recruitment and endothelial adhesion towards CyPA in vivo. In wild-type mice, we observed a downregulation of RAGE on leucocytes when endogenous extracellular CyPA was reduced. We furthermore evaluated the role of RAGE for platelet activation and thrombus formation upon CyPA stimulation. CyPA-induced activation of platelets was found to be dependent on RAGE, as inhibition of RAGE, as well as platelets from Ager-/- mice showed a diminished activation and thrombus formation upon CyPA stimulation. CyPA-induced signalling through RAGE was found to involve central signalling pathways including the adaptor protein MyD88, intracellular Ca2+ signalling, and NF-κB activation.
CONCLUSION: We propose RAGE as a hitherto unknown receptor for CyPA mediating leucocyte as well as platelet activation. The CyPA-RAGE interaction thus represents a novel mechanism in thrombo-inflammation.
OBJECTIVE: Elevation of Troponin I (TnI) in spontaneous subarachnoid hemorrhage (SAH) patients is a well-known phenomenon and associated with cardiopulmonary complications and poor outcome. The present study was conducted to investigate the association of the TnI value on admission, and the occurrence of cerebral vasospam in SAH patients.
PATIENTS AND METHODS: A total of 142 patients with SAH, who were admitted to the neurosurgical intensive care unit (ICU) between December 2014 and January 2021 were evaluated. Blood samples were drawn on admission to determine TnI value. Each patient's demographic, radiological and medical data on admission, the modified Ranking Scale score at discharge as well as continuous measurements of transcranial Doppler sonography were analyzed. A maximum mean flow velocity (MMFV) > 120 cm/sec was defined as any vasospasm. These were stratified into severe vasospasms, which were defined as at least two measurements of MMFVs > 200 cm/sec or an increase of MMFV > 50 cm/sec/24 h over two consecutive days or a new neurological deterioration and mild vasospasm defined as MMFVs > 120 cm/sec in absence of severe vasospasm criteria. The total study population was dichotomized into patients with an initially elevated TnI (>0.05 µg/L) and without elevated TnI (≤0.05 μg/L).
RESULTS: A total of 52 patients (36.6%) had an elevated TnI level upon admission, which was significantly associated with lower GCS score (p < 0.001), higher WFNS score (p < 0.001) and higher Fisher grade (p = 0.01) on admission. In this context a higher rate of ischemic brain lesions (p = 0.02), a higher modified Rankin Scale score (p > 0.001) and increased mortality (p = 0.02) at discharge were observed in this group. In addition, TnI was identified as an independent predictor for the occurrence of any vasospasm and severe vasospasm.
CONCLUSION: An initially elevated TnI level is an independent predictor for the occurrence of any and severe vasospasm in patients with SAH.
Participants received cinacalcet at a starting dose of 30 mg orally once daily for 52 weeks. Cinacalcet dose was titrated every 4 weeks during the dose-titration phase and during study visits in the maintenance phase based on intact parthyroid hormone (iPTH) values, corrected total serum calcium values, and safety assessments.
The invention relates to sophoroselipids of formula (I) wherein R4 represents H, -CH2CH3, -CH2CH2CH3, n is an integer number from 2 to 27, R1 and R2 represent, independently from each other, H or a group of formula (II), and R3 represents H or -OH. The invention also relates to a method for producing sophoroselipids of formula (I) wherein R1, R2, R3 and n have the aforementioned meanings and R4 represents -CH3, -CH2CH3 or -CH2CH2CH3. According to this method, a yeast capable of secreting a sophoroselipid in the form of a lactone in the culture excess, is fermented in a culture medium containing a glycerin. a succinate, a mono-, di- and/or tri-saccharide and a lipid precursor, said sophoroslipid being then isolated from the culture solution. The inventive method is characterised in that the lipid precursor contains one or more 3-alkanols, 4-alkanols or an alkanone with a chain length from 6 to 30 carbon atoms or mixtures of said alkanoistalkanone. Furthermore, according to a variant of the aforementioned method for producing sophoroselipids of formula (I), wherein R1, R2, R3 and n have the meanings aforementioned and R4 represents -CH3, -CH2CH3 or -CH2CH2CH3, the culture medium is maintained during fermentation under a reduced oxygen concentration. The new sophoroselipids may be used, e.g., as surfactants, cosmetics, disinfecting agents or pharmaceutical products.
Acute kidney injury (AKI) in children is associated with increased morbidity, reduced health-related quality of life, greater resource utilization, and higher mortality. Improvements in the timeliness and precision of AKI diagnosis in children are needed. In this report, we highlight existing, novel, and on-the-horizon diagnostic and risk-stratification tools for pediatric AKI, and outline opportunities for integration into clinical practice. We also summarize pediatric-specific high-risk diagnoses and exposures for AKI, as well as the potential role of real-time risk stratification and clinical decision support to improve outcomes. Lastly, the key characteristics of important pediatric AKI phenotypes will be outlined. Throughout, we identify key knowledge gaps, which represent prioritized areas of focus for future research that will facilitate a comprehensive, timely and personalized approach to pediatric AKI diagnosis and management.
Copeptin represents a new biomarker, direct mirror of AVP release with remarkable characteristics (stable, rapid determination, small blood volume). Copeptin has become a diagnostic tool in adult PPS and eliminated WDT in the diagnostic process. In children, basal copeptin values help for NDI and to exclude CDI (basal copeptin threshold \> 30 and \>3.53 pmol/l (Se 100%, Sp 87.4%), respectively). Below 3.53 pmol/l, basal copeptin performance was inadequate to discriminate PP and CDI, highlighting the relevance of the stimulated copeptin study to improve this strategy.
A dentifrice composition comprises a fluoride which releases fluoride ions in water, a calcium polyphosphate polishing agent and a calcium ion suppression agent.  Suitable fluorides are: sodium and potassium fluoride, stannic or stannous fluoride and stannous chlorofluoride. The polishing agent may be an essentially water insoluble calcium salt of a polyphosphoric acid, e.g. calcium pyrophosphate, sodium calcium pyrophosphate, and calcium triphosphate.  The calcium ion suppression agents may be water soluble inorganic acid polyphosphates such as disodium diacid pyrophosphate or dipotassium diacid pyrophosphate; or organic chelating agents such as water soluble salts of organic polycarboxylic acids e.g. sodium or potassium citrate, tetrasodium ethylene diamine tetraacetate.  The preparations may also contain a detergent material, e.g. saturated higher aliphatic acyl amides or lower aliphatic aminocarboxylic acid compounds, such as; N - lauroyl sarsocine or the sodium, potassium or ethanolamine salts of N - lauroyl; myristoyl or palmitoyl sarcosides. The preparations may also contain, saccharin; flavouring, whitening and emulsifying agents; preservatives, and chlorophyll compounds. Specifications 728,243 and 753,979 are referred to.
Techniques are provided for procuring healthcare services. A request to procure healthcare services for a patient is obtained. Provider subscription profiles corresponding to healthcare providers are generated based on subscriber information and provider subscription criteria. Bid auction invitations are generated by assigning a bid invitation ranking to each provider subscription profile and selecting healthcare providers to participate in a bid auction based on the bid invitation rankings. A pre-bill claim form is generated based on at least one bill template related to one or more medical classification codes related to the healthcare services. An auction engine is configured to conduct a bid auction among the selected healthcare providers, which results in a selection of a healthcare provider for the healthcare services and, upon confirmation that the healthcare services have been provided, a computing device or network platform is configured to take an action based on the pre-bill claim form.
PURPOSE: A pharmaceutical composition containing a Perilla frutescens extract or benzo[b]naphtha[2,3-d]thiophene isolated from the extract for preventing or treating neuronal diseases is provided to suppress acetylcholine esterase(AChE), and to effectively prevent, treat, or relieve Alzheimer's disease, dementia, and neurodegenerative diseases. CONSTITUTION: A pharmaceutical composition for preventing or treating neuronal diseases contains a Perilla frutescens extract as an active ingredient. The extract is prepared by using an organic solvent, water, or a mixture thereof. The extract is an ethanol extract. The extract is also an ethyl acetate fraction which is prepared by extracting with ethanol and sequentially fractioning a residue of the Perilla frutescens extract with hexane, chloroform, and ethyl acetate. The extract is a fraction which is prepared by performing silicagel column chromatography using chloroform and ethanol in a ratio of 100:0-80:20. The extract also contains benzo[b]naphtha[2,3-d]thiophene.
Study TMC114-C211

The safety assessment is based on all safety data from the Phase 3 trial TMC114-C211 comparing PREZISTA/ritonavir 800/100 mg once daily versus lopinavir/ritonavir 800/200 mg per day in 689 antiretroviral treatment-naïve HIV-1-infected adult subjects. The total mean exposure for subjects in the PREZISTA/ritonavir 800/100 mg once daily arm and in the lopinavir/ritonavir 800/200 mg per day arm was 95.0 and 91.4 weeks, respectively.

The majority of the adverse drug reactions (ADRs) reported during treatment with PREZISTA/ritonavir 800/100 mg once daily were mild in severity. The most common clinical ADRs to PREZISTA/ritonavir 800/100 mg once daily (≥ 5%) of at least moderate intensity (≥ Grade 2) were diarrhea, headache, abdominal pain and rash. 2.3% of subjects in the PREZISTA/ritonavir arm discontinued treatment due to ADRs.

ADRs to PREZISTA/ritonavir 800/100 mg once daily of at least moderate intensity (≥ Grade 2) in antiretroviral treatment naïve HIV-1-infected adult subjects are presented in Table 3 and subsequent text below the table.
INTRODUCTION: Sepsis, a life-threatening syndrome, is often accompanied by tachycardia in spite of hypovolemia and hypotension have been corrected. Recently, relevant studies have shown that sustained tachycardia in sepsis was related to high mortality, and appropriate control of heart rate (HR) could improve prognosis. Ivabradine reduces HR directly without a negative inotropic effect through inhibition of the If ionic current, which is different from the traditional rate control drug (beta-blockers).
METHODS AND ANALYSIS: This is a prospective, multicenter, randomized, open label study designed to investigate the effect of heart rate control with ivabradine on hemodynamic in patients with sepsis. Our study will enroll 172 patients with sepsis as defined by The Third International Consensus Definitions for Sepsis and Septic Shock criteria with sinus rate of 95 bpm or higher despite a hemodynamic optimization. Patients will be randomly assigned to standard treatment group (GS) or ivabradine group (GI, standard treatment for sepsis plus enteral ivabradine). Patients in GI will receive ivabradine to maintain HR between 70 and 94 bpm. The primary outcome is the difference of a reduction in HR below 95 bpm and the effect of ivabradine on hemodynamics between GI and GS group within the first 96 h after randomization. The secondary outcomes include organ function measures, the difference in SOFA score, incidence of adverse events, need for organ support, length of ICU stay, and 28-day overall mortality.
DISCUSSION: There are limited studies on ivabradine to control heart rate in patients with sepsis. Our study aims to evaluate whether direct sinus node inhibition can improve hemodynamics, as well as its impact on organ function and prognosis in patients with sepsis, so as to provide evidence for the safe usage in clinical practice.
TRIAL REGISTRATION: ClinicalTrials.gov NCT05882708. Registered on May 11, 2023, https://clinicaltrials.gov/ct2/show/NCT05882708 .
PROBLEM TO BE SOLVED: To obtain a solid dispersion for medicine having improved stability in a typical storage surrounding, and including dispersion of a medicine with a low solubility in a medical polymer, capable of providing excellent biological utility. SOLUTION: This composition comprises a medicine with a low solubility, and at least one polymer. At least the majority of the medicine in the dispersion is amorphous. The polymer has at least 100 deg.C glass transition temperature measured in 50% relative humidity. In the other aspect, the composition comprises the same composition with the proviso that the dispersion has at least 50 deg.C glass transition temperature in 50% humidity. In another aspect, the composition contains the medicine with the low solubility and the stabilizing polymer. At least the majority of the medicine in the dispersion is amorphous. The composition also contains a concentration-increasing polymer capable of increasing the concentration of the medicine in a used environment.  The stabilizing polymer has a glass transition temperature higher than that of the concentration-increasing polymer in the 50 humidity.
PURPOSE:To provide the titled composition having improved discoloration resistance, mechanical strength and adhesivity to dental metals and tooth, by using an organic peroxide, an aromatic secondary or tertiary amine, and barbituric acid as the essential components of a curing agent for a radically polymerizable monomer. CONSTITUTION:The objective dental restoration composition curable at normal temperature and useful as a resin for bed, dental cement, adhesive, composite, etc., is composed of (A) 100pts.(wt.) of a radically polymerizable monomer such as methyl methacrylate and (B) a curing agent containing (i) 0.05-5pts. of an organic peroxide such as benzoyl peroxide, (ii) 0.05-5pts. of an aromatic secondary and/or tertiary amine such as N-di(beta-hydroxyethyl)-p-toluidine and (iii) 0.01-10pts. of barbituric acid and/or its derivative such as 5-butyl derivative, and if necessary, (iv) an acid anhydride or a phosphoric acid ester. The composition is resistant to discoloration, and exhibits excellent mechanical strength and high adhesivity.
Obesity has emerged as a significant global health burden, exacerbated by serious side effects associated with existing anti-obesity medications. Celastrol (CLT) holds promise for weight loss but encounters challenges related to poor solubility and systemic toxicity. Here, we present chondroitin sulfate (CS)-derived micelles engineered for adipocyte-specific targeting, aiming to enhance the therapeutic potential of CLT while minimizing its systemic toxicity. To further enhance adipocyte affinity, we introduced a biguanide moiety into a micellar vehicle. CS is sequentially modified with hydrophilic metformin and hydrophobic 4-aminophenylboronic acid pinacol ester (PBE), resulting in the self-assembly of CLT-encapsulated micelles (MET-CS-PBE@CLT). This innovative design imparts amphiphilicity via the PBE moieties while ensuring the outward exposure of hydrophilic metformin moieties, facilitating active interactions with adipocytes. In vitro studies confirmed the enhanced uptake of MET-CS-PBE@CLT micelles by adipocytes, while in vivo studies demonstrated increased distribution within adipose tissues. In a diet-induced obese mouse model, MET-CS-PBE@CLT exhibited remarkable efficacy in weight loss without affecting food intake. This pioneering strategy offers a promising, low-risk, and highly effective solution to address the global obesity epidemic.
Sevoflurane can attenuate lung ischaemia‒reperfusion injury (LIRI). However, the protective mechanism is unclear. In this study, we developed a LIRI model in vivo that animals (SD, n = 15) were subjected to the administration of 2.2 % sevoflurane 30 min before the onset of left pulmonary artery clamping for 45 min, which was then followed by 60 min of reperfusion treatment. Then, transcriptome sequencing was used to analyse lung tissues. Autophagy inhibition (3-MA) and Rac1-overexpression transfection plasmids were used in BEAS-2B cells, and BEAS-2B cells were subjected to hypoxia reoxygenation (H/R) and sevoflurane treatment. In both animal tissue and cells, inflammatory cytokines and apoptotic and autophagy molecules were measured by quantitative real-time PCR, western blotting and immunostaining. As a result, decreased arterial partial oxygen and damage to the histological structure of lung tissues were observed in LIRI model rats, and these effects were reversed by sevoflurane treatment. Activation of inflammation (elevated IL-1β, IL-6, and TNF-α) and apoptosis (elevated cleaved caspase3/caspase3 and Bax, degraded expression of Bcl2) and inhibition of autophagy (elevated P62, degraded expression of Beclin1 and LC3-II/LC3I) in the model group were ameliorated by sevoflurane. Transcriptome sequencing indicated that the PI3K/Akt pathway regulated by Rac1 plays an important role in LIRI. Furthermore, overexpression of Rac1 in a cell line inhibited the protective effect of sevoflurane in LIRI. Autophagy inhibition (3-MA) also prevented the protective effect of sevoflurane on inflammation and apoptosis. As shown in the present study, sevoflurane enhances autophagy via Rac1/PI3K/AKT signalling to attenuate lung ischaemia‒reperfusion injury.
NEW MATERIAL:A bisindolinone compound selected from structural isomers of a lower alkylindirubin expressed by formula I (R is CH3 or C2H5), lower alkylindigo (R is CH3, C2H5 or n-C3H7) and lower alkylisoindigotin expressed by formula III (R is same as in formula II). EXAMPLE:N-Ethylindigo. USE:A carcinostatic agent. The compound expressed by formula I has about the same antitumor action as that of the well-known indirubin, but the compounds expressed by formulas II and III exhibit remarkable antitumor action. This novel compound, derived from herbal roots and tree barks, and used as herbal medicines have no acute and chronic toxicity to human bodies and animals, and side effects are not considered. PREPARATION:A mixture of indigo with dimethylformamide is added to a stirred suspension of 60% NaOH in purified dimethylformamide, and the resultant mixture is stirred at room temperature for 2hr. C2H5I is then added thereto and reacted to afford the compound expressed by formula II (R is C2H5).
Quetiapine XR will be titrated according to the following pattern: Seroquel XR 300 mg on day 1 and Seroquel XR 600 mg on day 2. On day 3, the dosage could be either maintained at 600 mg/day or continued up to 800 mg/day or if the 600 mg dose is not tolerated, the dose could then be reduced to 400 mg/day. Following this, subjects will be flexibly dosed, according to clinical judgment of the investigator, between 400 mg/day and 800 mg/day with minimum dose adjustments of 200 mg/day. This adjustment can be performed at anytime during the study but should not take place within a week from last cognitive assessment, planned at month 6. An overlap of at least 4 days but not more than 2 weeks with the previous antipsychotic will be allowed with decreasing doses on a two-week period.
Mindfulness-based mandala activity was applied to the intervention group via the zoom online program. Students will be divided into groups of 6-10 and mandala activities will be carried out. 3 weeks of mandala activity, breathing exercises, affirmations, etc. a therapeutic application program was created and implemented.
Cardiovascular diseases pose a significant global health concern, particularly among the elderly population, leading to a surge in surgical interventions. Enhanced Recovery After Surgery (ERAS®) protocols, specifically ERAS® Cardiac, target improved perioperative pain management to optimize patient outcomes. Effective pain control aims to alleviate acute discomfort, prevent chronic pain development, facilitate early mobilization, reduce hospital stays, and enhance patient satisfaction and functional recovery. While pain intensity peaks within the initial days following cardiac surgery and gradually subsides, inadequate acute pain management can predispose patients to chronic pain, impairing their quality of life. Multimodal opioid-sparing analgesia strategies are recommended, with recent advancements in ultrasound-guided regional anesthesia techniques showing promise in enhancing acute pain relief and reducing opioid consumption, particularly through truncal fascial plane blocks and parasternal blocks. However, the impact of these techniques on chronic postsurgical pain remains incompletely understood. This multicenter study aims to investigate the incidence of chronic postsurgical pain following cardiac surgery, exploring the influence of various factors and their implications on patients' quality of life.